163 related articles for article (PubMed ID: 20182874)
1. Characterization of human CD4 helper T cell responses against Aurora kinase A.
Kobayashi H; Azumi M; Hayashi S; Sato K; Aoki N; Kimura S; Kakizaki H; Nagato T; Harabuchi Y; Tateno M; Celis E
Cancer Immunol Immunother; 2010 Jul; 59(7):1029-39. PubMed ID: 20182874
[TBL] [Abstract][Full Text] [Related]
2. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
3. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
4. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
5. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
6. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
[TBL] [Abstract][Full Text] [Related]
7. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.
Singh R; Singh S; Sharma PK; Singh UP; Briles DE; Hollingshead SK; Lillard JW
PLoS One; 2010 Feb; 5(2):e9432. PubMed ID: 20195541
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase as an immunotherapeutic target.
Kobayashi H; Azumi M; Kimura Y; Sato K; Aoki N; Kimura S; Honma M; Iizuka H; Tateno M; Celis E
Cancer Immunol Immunother; 2009 Jun; 58(6):931-40. PubMed ID: 18941742
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
10. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
[TBL] [Abstract][Full Text] [Related]
11. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
12. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
Kobayashi H; Omiya R; Sodey B; Yanai M; Oikawa K; Sato K; Kimura S; Senju S; Nishimura Y; Tateno M; Celis E
Clin Cancer Res; 2003 Nov; 9(14):5386-93. PubMed ID: 14614024
[TBL] [Abstract][Full Text] [Related]
13. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF
Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
15. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.
Bobinet M; Vignard V; Rogel A; Khammari A; Dreno B; Lang F; Labarriere N
PLoS One; 2012; 7(12):e51716. PubMed ID: 23284752
[TBL] [Abstract][Full Text] [Related]
16. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
18. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
20. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
